Key Highlights
- Dr. R. Todd Plott, a board‑certified dermatologist with decades of experience, joins the board, increasing its size.
- The company continues its Phase 1b trial (NCT# 06014086) of PH‑762 for cutaneous cancers as it prepares for upcoming shareholder meetings.
- The appointment underscores Phio’s focus on strengthening clinical oversight for its dermatology pipeline.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) disclosed that its board of directors has been expanded with the addition of Dr. R. Todd Plott, M.D. A board‑certified dermatologist who previously served on an FDA advisory committee.
Dr. Plott brings extensive clinical and research expertise in skin‑cancer therapies, directly aligning with Phio’s INTASYL‑based program for cutaneous malignancies. The company’s valuation remains modest, reflecting its early‑stage development status.
This board change follows a series of recent governance updates filed with the SEC.
Board Expansion Details
The board’s composition grew from five members to six, with Dr. Plott also assuming a role on the Governance Committee. His background includes senior positions in dermatologic research, a portfolio of patents, and experience on an FDA advisory panel focused on dermatology and ophthalmology.
By broadening the board, Phio signals a strategic intent to deepen clinical expertise as it advances upcoming dermatology‑focused trials.
Governance and Compensation
Along with his appointment, Dr. Plott entered into Phio’s standard indemnification agreement, which provides coverage for legal expenses incurred in the course of board service. He will receive the same compensation and equity awards granted to other non‑employee directors, as detailed in the company’s most recent Form 10‑K filing.
No special arrangements or related‑party transactions were disclosed, and the filing confirmed that no current or proposed deals involve Dr. Plott or his immediate family. This framework reflects Phio’s approach to attracting seasoned talent while managing fiduciary risk.
Market Context and Immediate Signal
Within the broader biotech sector, peers have shown mixed performance, with some companies experiencing modest share price movements. Phio’s stock has exhibited limited volatility, suggesting that investors are awaiting substantive data on the PH‑762 program before reassessing valuation. The board appointment is viewed as a positive signal of the company’s commitment to strong clinical oversight, though it has not yet generated pronounced trading activity.
Upcoming Catalysts
Phio’s next material event is its upcoming annual meeting of shareholders, where Dr. Plott will serve through the remainder of the year. Positive outcomes could validate the board’s decision to deepen dermatologic expertise and potentially influence market perception.
Investors are encouraged to monitor trial results and any related FDA communications as primary drivers of short‑term momentum. The information herein is based on the Form 8‑K filed on 21 July 2026, with the press release attached hereto.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...